https://www.thebodypro.com/category/hiv-treatments-in-development/tag/international-aids-conference
HIV Treatments in Development

International AIDS Conference

The Latest

Promo Image

HIV Drug Updates

Complera, the newest single tablet regimen (STR), comprised of rilpivirine (Edurant) plus emtricitabine/tenofovir (Truvada), continues to hold its own. Previously, it had been shown to be non-inferior to Atripla, another STR, made of efavirenz (Susti...

Promo Image

Towards an HIV Cure: Early Developments in the Field

After the announcement of the IAS Towards an HIV Cure scientific strategy at this third IAS pre-conference symposium, held this year from 20-21 July, any advances in the field of cure research will come under a new emphasis.

This strategy outlines t...

Promo Image

Dolutegravir vs. Raltegravir in Treatment-Naive Patients: 48-Week Results From the SPRING 2 Study

Francois Raffi, from University of Nantes, France, presented the SPRING-2 study as an oral late breaker.

This was a randomised, double-blind, double-placebo controlled, non-inferiority study in treatment-naive patients. Participants (from Canada, U....

Daniel Douek: HIV Cure and Vaccine Approaches (Video) Img

Daniel Douek: HIV Cure and Vaccine Approaches (Video)

Daniel Douek, M.D., senior investigator at the National Institutes of Health, sits down with Jeff Taylor to discuss the current state of cure research and the development of theraputic and prophylactic vaccines for HIV. He also touches upon the need ...

Is the "Berlin Patient" No Longer Alone? Stem Cell Transplant Appears to Clear HIV in Two Men on Treatment Img

Is the "Berlin Patient" No Longer Alone? Stem Cell Transplant Appears to Clear HIV in Two Men on Treatment

Two HIV-infected men are showing no traces of HIV in their blood after going through stem cell transplants similar to the one "Berlin Patient" Timothy Brown received, according to a study presented at the XIX International AIDS Conference.

Cancer Drug Flushes Out Lurking AIDS Virus: Study Img

Cancer Drug Flushes Out Lurking AIDS Virus: Study

In a small pilot study, U.S. researchers have used the cancer drug vorinostat to revive and unmask latent HIV in volunteers' immune cells. The ability of HIV to lay dormant and "hidden" has posed a major obstacle to a cure; this approach aims to expo...

Promo Image

AIDS 2012: Closing in on a Cure

Three research teams have shared promising findings in the search for a cure this week at AIDS 2012. "I think today might be considered the day when the cure research agenda moves from the basic science lab into the clinic," said Steven Deeks of the ...

Jacob Lalezari: In HIV/AIDS, "Cure Is a Four-Letter Word" (Video) Img

Jacob Lalezari: In HIV/AIDS, "Cure Is a Four-Letter Word" (Video)

Jacob P. Lalezari, M.D., talks with IFARA about the coupled optimism and cautiousness regarding the search for an HIV cure. He explains each of the primary paths currently being explored toward the development of a cure and describes the progress we'...

Promo Image

Scientists Plan to Announce Research Strategy Aimed at Pursuing HIV/AIDS Cure, Wall Street Journal Reports

On July 19, ahead of the XIX International AIDS Conference in Washington, D.C., "prominent AIDS scientists plan to announce the first comprehensive research strategy aimed at pursuing new leads and addressing hurdles to a cure" for HIV/AIDS, the Wall...

Promo Image

Cenicriviroc for Inflammation and HIV

A company called Tobira Therapeutics is developing a drug called cenicriviroc (also known as TBR-652, formerly TAK-652). This drug has both anti-inflammatory and anti-HIV activity. Cenicriviroc works by blocking a receptor called CCR5, found on the s...